The Long-Term Outlook for MFN Pricing
An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.
The MFN Order is considered a potential solution for high drug prices, with implications beyond the US.
The Most-Favored-Nation Policy: Outlook and Implications Beyond US
Despite the success of the Inflation Reduction Act (IRA) in lowering prices for key Medicare prescription drugs, pressure continues to mount on pharmaceutical manufacturers to reduce prices.
The Trump administration's quest to put America first by further reducing prices of prescription drugs remains a key issue.
Author's Summary
MFN pricing analysis compares US costs with reference countries.
More News
- Joseph Parker vs Fabio Wardley - Results & Post-Fight Report
- SoftBank’s OpenAI ambition is far too grand for banks
- Internal Report Shows the Military Always Wanted to Join the Drug War
- Future of Longridge Soap Box Derby under threat due to lack of volunteers – Blog Preston
- Chhath Puja: When will Lord Surya appear in your city? Know sunrise and sunset times for all districts
- Nepal face 263-run chase in League 2 opener
- The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations | PharmExec
- Chaz Mostert makes it a Gold Coast double